The EMA’s CHMP adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Adstiladrin. Since Adstiladrin is an advanced therapy medicinal product, the… read more.
Colorectal cancer (CRC) is the second most common cause of cancer death in the United States and disproportionally impacts people who receive care in under-resourced settings. Fortunately, several… read more.
Boston Scientific announced FDA 510(k) clearance for the Asurys Fluid Management System, designed to provide irrigation and distention during endoscopic urologic procedures, including ureteroscopies. Ureteroscopy is a common… read more.
PROCEPT BioRobotics highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower urinary tract symptoms (LUTS), which include an upgrade of Aquablation therapy… read more.
One in ten emergency patients with visible blood in their urine die within three months of presenting at A&E, new research has found. The WASHOUT study, presented today… read more.
Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research. The findings are presented today… read more.
Shionogi & Co. Ltd. announced that its group company, Shionogi China Co., Ltd, has received approval from the National Medical Products Administration (NMPA) of China for cefiderocol for… read more.
Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer, offering a much-needed alternative… read more.
NICE (UK): Darolutamide with androgen deprivation therapy (ADT) can be used as an option to treat hormone-sensitive metastatic prostate cancer in adults, only if: i) docetaxel is not… read more.
UCLA research finds that fewer than 1 in 4 eligible younger adults completed colorectal cancer screenings after the United States Preventive Services Task Force (USPSTF) lowered the recommended… read more.
Patients with colon cancer who are using glucagon-like peptide-1 (GLP-1) receptor agonists for blood sugar regulation and/or weight control appear to have achieved a significantly lower risk of… read more.
Guardant Health Inc announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
